GLP-1 Medications and Cardiovascular Protection: The SELECT Evidence

Key Takeaways

• SELECT trial: semaglutide 2.4 mg reduced MACE by 20% over 3.3 years in adults with established CV disease and overweight/obesity (no diabetes required)
• FDA expanded Wegovy's label in 2024 to include cardiovascular risk reduction in this population
• Approximately half the benefit appears weight-mediated; the other half operates through additional mechanisms
• The cardiovascular indication is the strongest Medicare Part D coverage path for Wegovy, distinct from the weight-loss exclusion
• Tirzepatide's dedicated CV outcome trial (SURPASS-CVOT) is in progress with expected 2026-2027 readout

Direct answer

Semaglutide is the first GLP-1 medication with FDA approval for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity, granted in 2024 based on the SELECT trial. SELECT showed a 20% reduction in major adverse cardiovascular events over a median 3.3 years in 17,604 patients. The benefit is partly weight-mediated and partly attributable to additional mechanisms including blood pressure reduction, inflammation reduction, and possible direct vascular effects. The cardiovascular indication is the strongest Medicare coverage path for Wegovy and applies to secondary prevention (patients with prior MI, stroke, or peripheral artery disease).

Table of contents

1. The cardiovascular trial history before SELECT
2. SELECT design and primary outcomes
3. Secondary outcomes and subgroup analyses
4. The 2024 FDA cardiovascular indication
5. How much of the benefit is weight loss
6. STEP-HFpEF and heart failure
7. Primary versus secondary prevention
8. Other GLP-1 medications and CV outcomes
9. Medicare coverage through the CV indication
10. The contrary view: where caution is warranted
11. Decision framework
12. FAQ
13. Sources

The cardiovascular trial history before SELECT

GLP-1 medications have been studied for cardiovascular outcomes since the early 2010s, initially in diabetic populations:

Trial	Drug	Population	Finding
ELIXA (2015)	Lixisenatide	T2D post-ACS	Cardiovascular safety; no benefit
LEADER (2016)	Liraglutide	T2D with high CV risk	13% MACE reduction
SUSTAIN-6 (2016)	Semaglutide	T2D with high CV risk	26% MACE reduction
EXSCEL (2017)	Exenatide ER	T2D	Trend toward benefit; not significant
HARMONY (2018)	Albiglutide	T2D with CVD	22% MACE reduction
REWIND (2019)	Dulaglutide	T2D with CV risk factors	12% MACE reduction
SELECT (2023)	Semaglutide 2.4 mg	Overweight/obese with established CVD, no diabetes	20% MACE reduction
FLOW (2024)	Semaglutide 1.0 mg	T2D with CKD	24% kidney/CV reduction

The pre-SELECT picture established cardiovascular benefit of GLP-1 medications in diabetic patients with high CV risk. SELECT extended this to non-diabetic patients with overweight/obesity and established CV disease, opening a much larger eligible population.

SELECT design and primary outcomes

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) was designed to test whether semaglutide could reduce cardiovascular events in patients without diabetes. Lincoff et al. published in NEJM 2023.

Design summary:

• 17,604 adults aged 45 or older
• Established cardiovascular disease: prior MI, prior nonfatal stroke, or symptomatic peripheral artery disease
• BMI 27 or higher
• HbA1c below 6.5% (i.e., not diabetic)
• Semaglutide 2.4 mg weekly versus placebo
• Median follow-up 33 months (~3.3 years)
• Primary endpoint: 3-component MACE (cardiovascular death, nonfatal MI, or nonfatal stroke)

Approximate results:

Outcome	Semaglutide	Placebo	Effect
3-MACE primary endpoint	6.5%	8.0%	HR 0.80 (20% reduction, p < 0.001)
Cardiovascular death	2.5%	3.0%	HR 0.85
Nonfatal MI	2.7%	3.7%	HR 0.72
Nonfatal stroke	1.7%	1.9%	HR 0.93
All-cause death	4.3%	5.2%	HR 0.81
Body weight change	~ -9.4%	~ -0.9%	-

The benefit was driven primarily by nonfatal MI reduction. Stroke reduction trended favorable but was smaller. The all-cause mortality reduction is notable; few obesity or weight-related medications produce mortality benefit.

The effect emerged early. Kaplan-Meier curves separated within months, before substantial weight loss had accrued. This suggested the benefit was not solely weight-mediated.

Secondary outcomes and subgroup analyses

SELECT had multiple prespecified secondary endpoints and subgroup analyses:

• Cardiovascular composite including heart failure events: reduced
• Composite kidney endpoint: directionally favorable, smaller effect
• By baseline BMI: benefit consistent across BMI strata
• By age: benefit consistent across age groups
• By sex: similar benefit in men and women
• By baseline HbA1c (within non-diabetic range): benefit slightly larger in pre-diabetic subgroup
• By prior CV event type: benefit consistent across MI, stroke, and PAD subgroups

Safety findings:

• Standard GLP-1 GI side effects (more on semaglutide than placebo)
• Pancreatitis: small numeric excess, not statistically meaningful
• Gallbladder events: modest increase
• Suicidal ideation: no signal (the data contributed to the 2024 FDA review concluding no causal relationship)
• Diabetic retinopathy: small numeric excess in pre-diabetic patients who became diabetic during follow-up

The overall safety picture was reassuring. The cardiovascular benefit was achieved without significant new safety signals.

The 2024 FDA cardiovascular indication

The FDA expanded Wegovy's label in March 2024 to include cardiovascular risk reduction. The relevant labeling addition specified:

• Reduction of risk of cardiovascular death, MI, and stroke
• In adults with established cardiovascular disease
• And either overweight (BMI ≥27) or obesity

The indication did not require diabetes. This was the first FDA-approved cardiovascular risk reduction indication for a GLP-1 medication in a non-diabetic population.

Practical implications:

• Wegovy became prescribable specifically for CV risk reduction, not just for weight management
• Insurance plans had to consider whether their formulary excluded Wegovy for weight loss but should now cover for CV risk
• Medicare Part D coverage opened up; the CV indication is not subject to the weight-loss exclusion
• The patient population eligible expanded substantially beyond the diabetes-driven CV trials

Wegovy 2.4 mg was the SELECT dose and is the dose for the CV indication. Ozempic (semaglutide for diabetes) does not carry the same CV-with-overweight-without-diabetes indication; Ozempic's CV indication applies to type 2 diabetes plus established CVD.

How much of the benefit is weight loss

Mediation analyses from SELECT and surrounding work suggest the cardiovascular benefit is roughly half weight-mediated and half through other mechanisms.

Weight-mediated effects:

• Reduced cardiac workload
• Improved lipid profile
• Lower blood pressure
• Reduced insulin resistance
• Reduced inflammation related to adipose tissue

Non-weight-mediated effects:

• Direct anti-inflammatory effects (lower CRP, IL-6)
• Glycemic improvement in pre-diabetic patients
• Modest blood pressure reduction independent of weight
• Possible direct vascular effects (endothelial function)
• Heart rate increase (a complicating signal, since increased heart rate is generally associated with adverse outcomes; the net benefit despite this suggests other mechanisms compensate)

The early time-course of benefit (Kaplan-Meier curves separating within months, before substantial weight loss) suggests non-weight mechanisms contribute meaningfully. This is similar to SGLT2 inhibitors, where cardiovascular and kidney benefits appear too quickly to be fully weight or glucose mediated.

STEP-HFpEF and heart failure

Heart failure with preserved ejection fraction (HFpEF) is a common form of heart failure with limited treatment options. STEP-HFpEF (Kosiborod et al., NEJM 2023) tested semaglutide specifically in HFpEF with obesity.

Design:

• 529 patients with HFpEF and obesity (BMI 30+)
• Semaglutide 2.4 mg weekly versus placebo
• 52 weeks
• Co-primary endpoints: KCCQ-CSS (heart failure-specific quality of life) and body weight

Approximate results:

• KCCQ-CSS improvement: ~16.6 points on semaglutide vs ~8.7 on placebo
• Weight loss: ~13% on semaglutide vs ~3% on placebo
• 6-minute walk distance improved on semaglutide
• CRP and NT-proBNP reduced on semaglutide

STEP-HFpEF supported the application of semaglutide in obesity-related HFpEF, though formal FDA HFpEF indication has not been granted as of May 2026. STEP-HFpEF in type 2 diabetes (STEP-HFpEF DM) showed similar results.

Primary versus secondary prevention

SELECT enrolled secondary prevention (patients with established CV disease). The cardiovascular indication applies to that population.

Primary prevention (patients with risk factors but no established CV events) is a different question. Some analyses suggest GLP-1 medications may reduce CV events in high-risk primary prevention populations, but dedicated primary prevention trials in non-diabetic patients are limited.

Currently:

• Secondary prevention with overweight/obesity: Wegovy CV indication applies
• Primary prevention with high risk plus obesity: standard obesity indication applies; CV benefit is plausible but not separately indicated
• Primary prevention without obesity: GLP-1 medications are not appropriate based on current evidence

The distinction matters because primary prevention populations are much larger and would expand the eligible population if extended to them. Future trials may address this directly.

Other GLP-1 medications and CV outcomes

Cardiovascular evidence varies by GLP-1 medication:

Medication	CV outcome evidence	FDA CV indication
Semaglutide (Wegovy)	SELECT in CVD+overweight; strong	Yes, in CVD+overweight (2024)
Semaglutide (Ozempic)	SUSTAIN-6 in T2D+high CV risk; FLOW in T2D+CKD	Yes, in T2D with CVD
Liraglutide (Victoza)	LEADER in T2D+high CV risk	Yes, in T2D with CVD
Dulaglutide (Trulicity)	REWIND in T2D	Yes, in T2D with or without CVD
Tirzepatide (Mounjaro)	SURPASS-CVOT in progress	Not yet
Tirzepatide (Zepbound)	SURMOUNT-MMO in progress	Not yet for obesity-CV indication
Liraglutide (Saxenda)	Limited CV outcome data in obesity-only population	Not yet for obesity-CV indication

Tirzepatide CV indication is the most anticipated future label expansion. SURPASS-CVOT (in T2D) and SURMOUNT-MMO (in obesity) are running in parallel. Readouts in 2026-2027 will determine whether tirzepatide secures cardiovascular indications.

Medicare coverage through the CV indication

Medicare Part D excludes weight-loss medications under the Medicare Modernization Act. The cardiovascular indication for Wegovy is not weight loss; it is treatment of cardiovascular disease. CMS guidance in 2024 clarified that the CV indication is coverable under Part D.

Coverage criteria typically require:

• Age 45 or older
• Established cardiovascular disease (prior MI, stroke, or symptomatic PAD)
• BMI 27 or higher
• No active diabetes (for the Wegovy CV indication; T2D patients use Ozempic on T2D coverage)
• Sometimes documented evidence of lifestyle intervention

Plan implementation has been uneven. Some Medicare Part D plans embraced the CV indication promptly; others have been slow or restrictive. The 2025 Part D out-of-pocket cap of $2,000 annually limits maximum exposure for patients who do get coverage.

Medicare Advantage plans must meet Part D minimums. Many MA plans have added Wegovy under the CV indication.

The contrary view: where caution is warranted

Argument 1: SELECT was secondary prevention. The 20% MACE reduction applies to a specific high-risk population. Extrapolating to primary prevention or lower-risk patients is not directly supported by the data.

Argument 2: Treatment duration is unclear. SELECT followed patients for 3.3 years. Whether benefit persists at 5, 10, or 20 years on continuous treatment is unknown. Discontinuation effects on cardiovascular outcomes have not been studied.

Argument 3: Number needed to treat is meaningful but not dramatic. The absolute risk reduction in SELECT was approximately 1.5 percentage points over 3.3 years (8.0% to 6.5%). Number needed to treat to prevent one MACE event was approximately 67 patients over 3.3 years. This is a meaningful clinical effect, but not transformative for any given individual patient.

Argument 4: Cost-effectiveness is debated. Wegovy is expensive. The cost per cardiovascular event prevented is high. Whether health systems and payers find this acceptable varies.

Argument 5: Other established interventions also reduce CV events. Statins, blood pressure medications, antiplatelet therapy, and SGLT2 inhibitors all have established CV benefit at lower cost. Wegovy adds incremental benefit on top of, not instead of, standard care.

Argument 6: Heart rate increase is a complicating signal. GLP-1 medications increase resting heart rate modestly. Elevated heart rate is generally associated with adverse outcomes. The mechanism producing CV benefit despite this is worth understanding.

Decision framework

If you have established CV disease and BMI 27+: You fit the SELECT-derived Wegovy CV indication. Discuss with your cardiologist or primary care clinician. Coverage is more accessible than weight-loss-only indications.

If you have established CV disease and type 2 diabetes: Ozempic at the diabetes dose (up to 2.0 mg) has CV-with-T2D indication. Wegovy at the obesity dose may also be appropriate if BMI criteria met.

If you have high CV risk but no events yet, and BMI 30+: Standard obesity indication for Wegovy applies. CV benefit is plausible from SELECT-related populations but not formally a primary prevention indication.

If you have heart failure: If HFpEF with obesity, STEP-HFpEF supports use; coordinate with cardiology. HFrEF data are less specific.

If you are on standard CV medications: GLP-1 adds incremental benefit; it does not replace statins, antiplatelets, or blood pressure medications. The combination is typically more effective than any single intervention.

If you have cardiovascular contraindications: Specific contraindications to semaglutide (medullary thyroid cancer history, MEN-2 syndrome, severe gastroparesis) apply regardless of indication.

Compounded medication note for this topic

For GLP-1 Medications and Cardiovascular Protection: The SELECT Evidence, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

Do GLP-1 medications reduce cardiovascular events?

Yes. SELECT showed 20% MACE reduction with semaglutide in CV disease plus overweight/obesity. Multiple diabetes trials show CV benefit in T2D populations.

What did SELECT show?

20% reduction in CV death, nonfatal MI, and nonfatal stroke composite over 3.3 years. All-cause mortality also reduced.

Who qualifies for the Wegovy CV indication?

Adults 45+ with established cardiovascular disease (prior MI, stroke, or PAD) and BMI 27+. No diabetes required.

Does this apply to people without prior heart attacks?

Not directly. SELECT was secondary prevention. Primary prevention CV benefit is plausible but not separately indicated.

What about tirzepatide?

SURPASS-CVOT (T2D) and SURMOUNT-MMO (obesity) trials are in progress. CV indication for tirzepatide is anticipated 2026-2027 if results are positive.

Is the benefit mostly from weight loss?

Roughly half weight-mediated, half through other mechanisms (blood pressure, inflammation, vascular effects). Early Kaplan-Meier separation supports non-weight mechanisms.

Does Medicare cover Wegovy for CV protection?

Yes, the CV indication is coverable under Part D. Plan implementation varies.

Can I take this with heart failure?

HFpEF with obesity: STEP-HFpEF supports use. Coordinate with cardiology.

What about stroke survivors?

Prior stroke qualifies as established CV disease for the Wegovy CV indication.

Are there cardiovascular safety concerns?

Heart rate increase is documented. Net cardiovascular benefit despite this suggests other mechanisms compensate. Safety profile in SELECT was reassuring.

Should I stop my statin or BP medication?

No. GLP-1 adds to standard CV care; it does not replace it. Combinations are more effective.

How long should I take it?

Long-term, per current understanding. CV benefit accrues over years. Discontinuation effects on CV outcomes are unstudied.

Related guides

• BPC-157 for Heart Protection: Cardiovascular Peptide Research
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• GLP-1 Medications for PCOS: What the Evidence Actually Shows
• GLP-1 Medications for MASH and Fatty Liver: The Evidence Map
• GLP-1 Medications for Sleep Apnea: The SURMOUNT-OSA Evidence
• GLP-1 Medications and Alcohol Use Disorder: The Emerging Evidence

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
2. FDA Drug Label. Wegovy (semaglutide) Prescribing Information. Updated 2024 with CV indication.
3. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). NEJM. 2016.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). NEJM. 2016.
5. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019.
6. Hernandez AF et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes (HARMONY Outcomes). Lancet. 2018.
7. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). NEJM. 2023.
8. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients With Type 2 Diabetes (FLOW). NEJM. 2024.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
11. American Heart Association / American College of Cardiology Joint Guidelines on Primary and Secondary Prevention of Cardiovascular Disease. 2024 update.
12. Centers for Medicare and Medicaid Services. Part D Coverage Determinations for GLP-1 Cardiovascular Indications. 2024-2025.
13. European Society of Cardiology. Guidelines for the Management of Cardiovascular Disease in Patients with Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational content. Cardiovascular disease management requires cardiology or primary care involvement. This article is not a substitute for personalized clinical evaluation, and GLP-1 medications for cardiovascular indications should be coordinated with your cardiovascular care team.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved and has not been studied for cardiovascular outcomes. The CV indication applies specifically to brand-name Wegovy at the 2.4 mg dose used in SELECT. Compounded preparations are not interchangeable with brand-name products.

Results Disclaimer. SELECT described average outcomes across the trial population. Absolute risk reduction (about 1.5 percentage points over 3.3 years) is meaningful but modest for any individual patient. Number needed to treat estimates apply. Individual outcomes vary by adherence, comorbidities, and overall CV management.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.